-
启动子是DNA链上能与RNA聚合酶结合并启动基因转录的一段特殊序列;特异性启动子则是指能在特定的正常组织或肿瘤中被激活的启动子。现有研究已经证实,使用特异性启动子引导目的基因表达是一种特异性高且效果良好的肿瘤基因治疗方法[1]。近年来新的肿瘤靶向性特异性启动子层出不穷。本文将就特异性启动子在肿瘤基因治疗领域中的最新研究成果,按特异性启动子的作用类型进行综述。
肿瘤基因治疗相关的特异性启动子研究新进展
The new progress of the specific promoter for cancer gene therapy
-
摘要: 肿瘤基因治疗是一种在基因水平上治疗肿瘤的方法,是现有治疗肿瘤的先进方法之一。但是,肿瘤基因治疗技术还存在很多未解决的问题,例如目的基因表达的靶向性问题等。现有研究证实,使用特异性启动子可以提高肿瘤基因治疗的靶向性。启动子是指能启动mRNA转录的一段特异性DNA序列,特异性启动子是指仅在特定组织或肿瘤中才会被激活的启动子。该文将就肿瘤基因治疗相关的特异性启动子的近期研究,按启动子的作用类型进行综述。Abstract: Cancer gene therapy is a way to treat cancer at the gene level which is one of the effective methods for cancer therapy. But, there are still some outstanding problems, for example, the targeting of gene expression. Recent researches confirm that the specific promoter can improve the targeting in gene therapy. The promoter is a region of DNA which can initiates transcription of a particular gene. The specific promoter only can be activated in certain tissue or tumor. Based on the recent studies in this field, this article will introduce types and functions of specific promoters, which has been investigated in cancer gene therapy.
-
Key words:
- Promoter regions(Genetics) /
- Gene therapy /
- Targeted therapy
-
[1] Lu Y, Zhang Y, Chang G, et al. Comparison of prostate-specific promoters and the use of psp-driven virotherapy for prostate cancer[J/OL]. Biomed Res Int, 2013, 2013: 624632[2013-12-01]. http://www.ncbi.nlm.nih.gov/pubmed/23484134. [2] Baiz D, Hassan S, Choi YA, et al. Combination of the PI3k inhibitor zstk474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer[J]. Neoplasia, 2013, 15(10): 1172-1183. doi: 10.1593/neo.13986 [3] Claessens F, Rushmere NK, Davies P, et al. Sequence-specific binding of androgen-receptor complexes to prostatic binding protein genes[J]. Mol Cell Endocrinol, 1990, 74(3): 203-212. [4] Kesmodel S, Prabakaran I, Canter R, et al. Virus-mediated oncolysis of thyroid cancer by a replication-selective adenovirus driven by a thyroglobulin promoter-enhancer region[J]. J Clin Endocrinol Metab, 2005, 90(6): 3440-3448. doi: 10.1210/jc.2004-1801 [5] Spitzweg C, Baker CH, Bergert ER, et al. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression[J]. Hum Gene Ther, 2007, 18(10): 916-924. doi: 10.1089/hum.2007.081 [6] Chen EQ, Song XQ, Wang YL, et al. Construction of a highly-active, liver-specific transcriptional regulatory element through combination of the albumin promoter and alpha-fetoprotein enhancer[J]. Plasmid, 2010, 65(2): 125-131. [7] Horst M, Brouwer E, Verwijnen S, et al. Targeting malignant gliomas with a glial fibrillary acidic protein(GFAP)-selective oncolytic adenovirus[J]. J Gene Med, 2007, 9(12): 1071-1079. doi: 10.1002/jgm.1110 [8] Li W, Tan J, Wang P, et al. The glial fibrillary acidic protein promoter directs sodium/iodide symporter gene expression for radioiodine therapy of malignant glioma[J]. Oncol Lett, 2013, 5(2): 669-674. doi: 10.3892/ol.2012.1055 [9] Tanaka M, Inase N, Miyake S, et al. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma[J]. Anticancer Res, 2001, 21(1A): 291-294. [10] Jin C, Yu D, Ĉanĉer M, et al. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy[J]. Hum Gene Ther. 2013, 24(8): 766-775. doi: 10.1089/hum.2012.132 [11] Peng YF, Shi YH, Ding ZB, et al. a-Fetoprotein promoter-driven Cre/Loxp-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy[J/OL]. PLoS One, 2013, 8(2): e53072. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053072 [12] Zhou X, Xie G, Wang S, et al. Potent and specific antitumor effect for colorectal cancer by CEAand Rbdouble regulated oncolytic adenovirus harboring ST13 gene[J/OL]. PLoS One, 2012, 7(10): e47566. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0047566. [13] Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase(pCEA-TK /CD)[J]. Cancer Lett, 2012, 316(1): 31-38. doi: 10.1016/j.canlet.2011.10.015 [14] Guo X, Evans TR, Somanath S, et al. In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines[J]. Br J Cancer, 2007, 97(6): 745-754. doi: 10.1038/sj.bjc.6603930 [15] Yi T, Papadopoulos E, Hagner PR, et al. Hypoxia-inducible factor-1a(HIF-1a) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIFf4E1 in breast cancer cells under hypoxia conditions[J]. J Biol Chem, 2013, 288(26): 18732-18742. doi: 10.1074/jbc.M113.471466 [16] Doloff JC, Jounaidi Y, Waxman DJ. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT[J]. Cancer Gene Ther, 2011, 18(3): 153-166. [17] Trujillo MA, Oneal MJ, Davydova J, et al. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer[J]. Breast Cancer Res, 2009, 11(4): R53. doi: 10.1186/bcr2342 [18] Won YS, Lee SW. Cancer-specific induction of adenoviral E1A expression by group Iintron-based trans-splicing ribozyme[J]. J Microbiol Biotechnol, 2012, 22(3): 431-435. [19] Rajecki M, Sarparanta M, Hakkarainen T, et al. SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I[J/OL]. PLoS One, 2012, 7(3): e32871. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032871. [20] Li W, Tan J, Wang P, et al. Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells[J]. Cancer Biother Radiopharm, 2011, 26(4): 443-451. doi: 10.1089/cbr.2010.0908 [21] Chen J, Yang B, Zhang S, et al. Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma[J]. Cancer Gene Ther, 2012, 19(5): 328-335. doi: 10.1038/cgt.2012.5 [22] Maemondo M, Saijo Y, Narumi K, et al. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer[J]. Cancer Res, 2004, 64(13): 4611-4620. doi: 10.1158/0008-5472.CAN-03-2549 [23] Barker SD, Coolidge CJ, Kanerva A, et al. The secretory leukoprotease inhibitor(SLPI) promoter for ovarian cancer gene therapy[J]. J Gene Med, 2003, 5(4): 300-310. [24] Niu Y, Li JS, Luo XR. Enhancement of expression of survivin promoter-driven CD/TK double suicide genes by the nuclear matrix attachment region in transgenic gastric cancer cells[J]. Gene, 2014, 534(2): 177-182. doi: 10.1016/j.gene.2013.10.064 [25] 严泽军, 程跃, 蒋军辉, 等. Survivin启动子调控腺病毒介导富含亮氨酸重复和免疫球蛋白样结构域1基因治疗膀胱癌的实验研究[J].中华外科杂志, 2012, 50(8): 732-736. doi: 10.3760/cma.j.issn.0529-5815.2012.08.015
[26] Liu C, Sun B, An N, et al. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer[J]. Mol Oncol, 2011, 5(6): 545-554. [27] Xiang J, Ouyang Y, Cui Y, et al. Silencing of notch3 using shRNA driven by survivin promoter inhibits growth and promotes apoptosis of human T-cell acute lymphoblastic leukemia cells[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(1): 59-65. doi: 10.1016/j.clml.2011.07.005 [28] Ma J, Li M, Mei L, et al. Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells[J]. Genet Vaccines Ther, 2011, 9: 6. doi: 10.1186/1479-0556-9-6 [29] Li XH, Zhou P, Wang LH, et al. The targeted gene(KDRP-CD/TK)therapy of breast cancer mediated by SonoVue and ultrasound irradiation in vitro[J]. Ultrasonics, 2012, 52(1): 186-191. [30] 马晓方, 杜晓光, 辛现良, 等.肿瘤细胞恶性增殖和细胞周期调控改变的分子机制[J].现代生物医学进展, 2009, 9(5): 950-953.
[31] Sherr CJ, McCormick F. The RB and p53 pathways in cancer[J]. Cancer Cell, 2002, 2(2): 103-112. [32] Yan Y, Xu Y, Zhao Y, et al. Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model[J]. Tumour Biol, 2013: 35(2): 1113-1122. [33] Lin G, Lin MC, Lin S, et al. Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-Flurorouracil on nasopharyngeal carcinoma[J]. Cancer Biother Radiopharm, 2013, 27(7): 434-441. [34] Rein DT, Volkmer A, Beyer IM, et al. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus[J]. Gynecol Oncol, 2011, 123(1): 138-146. [35] Maeda T, O-Wang J, Matsubara H, et al. A minimum c-erbb-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir[J]. Cancer Gene Ther, 2001, 8(11): 890-896. doi: 10.1038/sj.cgt.7700389 [36] Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting[J]. Trends Genet, 2000, 16(4): 174-181. [37] Yu B, Zhang Y, Zhan Y, et al. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects[J]. Oncol Rep, 2011, 26(1): 255-264. [38] 李玮, 谭建, 王澎, 等. hTERT和GFAP启动子条件限制腺病毒介导放射性碘治疗脑胶质瘤[J].中华放射医学与防护杂志, 2014, 34(1): 1-6. doi: 10.3760/cma.j.issn.0254-5098.2014.01.001
计量
- 文章访问数: 3192
- HTML全文浏览量: 2015
- PDF下载量: 3